Quick Answer
Indivior Pharmaceuticals, Inc. reported Revenue (ASC 606) of $1.24 billion for fiscal year 2025.
Indivior Pharmaceuticals, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $1.24B | +4.3% |
| 2024 | $1.19B | +8.7% |
| 2023 | $1.09B | +21.3% |
| 2022 | $901.00M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $314.00M | +2.3% | +4.0% |
| June 30, 2025 | $302.00M | +1.0% | +13.5% |
| March 31, 2025 | $266.00M | -6.3% | -13.4% |
| September 30, 2024 | $307.00M | — | +2.7% |
| June 30, 2024 | $299.00M | — | +5.3% |
| March 31, 2024 | $284.00M | — | — |
- Indivior Pharmaceuticals, Inc. showed an increase of +4.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2022–2025 period, Indivior Pharmaceuticals, Inc.’s revenue (asc 606) has grown by 37.5% (from $901.00 million to $1.24 billion).
- The most recent figure is from Indivior Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: